Drug Cost Control in Oncology

The Orphan Drug Act in the Modern Drug Pricing Era

First announced in September 2025, the online platform is set to offer access to prescription medications at steep discounts, with potential savings in the millions.

February 3rd 2026

Express Scripts Avoids Fines but Agrees to Major Structural Overhaul

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Insulin syringe | Image Credit: © ixel-Shot-stock.adobe.com

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin.

January 20th 2026

Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Prescription drugs on a money banknotes. Concept of healthcare costs - Vitalii - stock.adobe.com.jpeg

New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq

Finance Committee leaders propose expanding Medicare negotiation, curbing middlemen, and reinvesting in biomedical innovation as part of a 2026 health care affordability strategy.

TrumpRx Launch Brings Savings—and Uncertainty

The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.

Related Content

The Orphan Drug Act in the Modern Drug Pricing Era

First announced in September 2025, the online platform is set to offer access to prescription medications at steep discounts, with potential savings in the millions.

February 3rd 2026

Express Scripts Avoids Fines but Agrees to Major Structural Overhaul

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin.

January 20th 2026

Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq

Finance Committee leaders propose expanding Medicare negotiation, curbing middlemen, and reinvesting in biomedical innovation as part of a 2026 health care affordability strategy.